Squarepoint
ATOS icon

Squarepoint’s Atossa Therapeutics ATOS Stock Holding History

Squarepoint’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,890
Closed -$220K – 4252
2025
Q3 		$220K Buy
16,890
+4,816
+40% +$59.5K ﹤0.01% 3883
2025
Q2 		$150K Sell
12,074
-19,859
-62% -$237K ﹤0.01% 4062
2025
Q1 		$322K Buy
+31,933
New +$388K ﹤0.01% 3686
2024
Q4 		– Sell
-842
Closed -$19.2K – 5015
2024
Q3 		$19.2K Sell
842
-3,594
-81% -$72.6K ﹤0.01% 4024
2024
Q2 		$79.2K Sell
4,436
-2,989
-40% -$66.1K ﹤0.01% 3841
2024
Q1 		$200K Buy
7,425
+3,221
+77% +$51.7K ﹤0.01% 3618
2023
Q4 		$55.5K Buy
+4,204
New +$45.4K ﹤0.01% 3836
2022
Q1 		– Sell
-1,835
Closed -$44K – 2803
2021
Q4 		$44K Buy
+1,835
New +$67.2K ﹤0.01% 3037
2021
Q3 		– Sell
-12,551
Closed -$1.19M – 2892
2021
Q2 		$1.19M Buy
+12,551
New +$664K ﹤0.01% 1516

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Squarepoint's ATOS Position: Q4 2025 in Review

Squarepoint sold out of Atossa Therapeutics (ATOS) in Q4 2025, closing a stake of 16,890 shares — an estimated $220K sold.

Squarepoint first reported a position in ATOS in Q2 2021 and held it in 9 quarters. The position peaked at $1.19M in Q2 2021. 67 funds tracked by Wall St. Rank hold ATOS as of Q4 2025.

  • Squarepoint reported no remaining Atossa Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 16,890 Atossa Therapeutics shares in Q4 2025, an estimated $220K.
  • Squarepoint first reported a position in Atossa Therapeutics in Q2 2021 and held it in 9 quarters.
  • Squarepoint's Atossa Therapeutics position peaked at $1.19M in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.